載入...
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30–50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthroug...
Na minha lista:
| 發表在: | Biomed Res Int |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Hindawi Publishing Corporation
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4573228/ https://ncbi.nlm.nih.gov/pubmed/26421294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/595894 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|